The 5-base solution uses a combination of Illumina proprietary innovations, including novel conversion chemistry and cutting-edge algorithms, to provide accurate genetic variant and methylation detection in a single, easy-to-use assay.

While conventional methylation conversion technologies convert unmethylated cytosine to thymine, Illumina proprietary conversion chemistry selectively converts methylated cytosine to thymine. As the majority of cytosines in a healthy human genome are unmethylated, selective conversion of methylated cytosine produces higher complexity libraries and, when combined with novel informatics, provides comprehensive, cost-effective 5-base insights.

• 5-base insights: Accurate genetic variant and methylation detection in a single assay.
• Simplicity: Single-step conversion and library prep completed in a single day.
• Flexibility: Compatible with different sample types and methods, including PCR+, enrichment, and PCR-Free.
• Affordability: Efficient sequencing for 5-base insights.
• Seamless solution from single provider: Illumina library prep-through-analysis solution and support.

The solution will be scalable on Illumina mid- to high-throughput sequencing platforms: the NextSeq 2000 System and NovaSeq X Series.

The bioinformatics solution does not require advanced expertise. It offers highly accurate variant and methylation detection. This is a simple, powerful, and easy-to-use multiomic analysis solution. Insights from Illumina Connected Multiomics are powered by DRAGEN analysis.